$378 Million is the total value of Paradigm Biocapital Advisors LP's 25 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 43.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Buy | ASCENDIS PHARMA A/Ssponsored adr | $37,745,000 | +28.6% | 321,621 | +47.4% | 9.98% | +19.1% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $33,491,000 | +46.6% | 966,827 | +23.9% | 8.86% | +35.7% |
| ARVN | Buy | ARVINAS INC | $33,067,000 | +49.9% | 491,333 | +83.0% | 8.74% | +38.8% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $30,225,000 | +68.0% | 831,728 | +115.5% | 7.99% | +55.5% |
| SRRA | Buy | SIERRA ONCOLOGY INC | $24,721,000 | +139.4% | 771,314 | +62.4% | 6.54% | +121.7% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $23,224,000 | -2.8% | 1,256,051 | +3.9% | 6.14% | -10.0% |
| INCY | New | INCYTE CORP | $18,618,000 | – | 234,419 | +100.0% | 4.92% | – |
| ISEE | Buy | IVERIC BIO INC | $15,322,000 | +12.4% | 910,416 | +11.6% | 4.05% | +4.0% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $15,109,000 | -6.2% | 907,428 | +7.5% | 4.00% | -13.2% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $14,926,000 | +224.7% | 499,190 | +271.8% | 3.95% | +200.6% |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $14,334,000 | – | 136,243 | +100.0% | 3.79% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $13,570,000 | – | 75,635 | +100.0% | 3.59% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $12,190,000 | +22.9% | 701,356 | +54.8% | 3.22% | +13.8% |
| CCCC | Buy | C4 THERAPEUTICS INC | $12,118,000 | +45.4% | 499,496 | +93.0% | 3.20% | +34.6% |
| OYST | Buy | OYSTER PT PHARMA INC | $11,497,000 | +107.0% | 987,698 | +224.6% | 3.04% | +91.7% |
| PRTA | New | PROTHENA CORP PLC | $9,799,000 | – | 267,946 | +100.0% | 2.59% | – |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $9,608,000 | +20.2% | 227,034 | +80.4% | 2.54% | +11.3% |
| MRUS | New | MERUS N V | $6,603,000 | – | 249,738 | +100.0% | 1.75% | – |
| VOR | Buy | VOR BIOPHARMA INC | $5,402,000 | -26.1% | 894,404 | +42.1% | 1.43% | -31.6% |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $5,370,000 | +28.0% | 1,157,246 | +37.9% | 1.42% | +18.5% |
| FULC | New | FULCRUM THERAPEUTICS INC | $5,037,000 | – | 212,961 | +100.0% | 1.33% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $3,016,000 | – | 336,229 | +100.0% | 0.80% | – |
| GRCL | Buy | GRACELL BIOTECHNOLOGIES INCsponsored ads | $1,825,000 | -44.6% | 783,445 | +43.6% | 0.48% | -48.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-02 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.